Anillo vaginal anticonceptivo (MyRing®): estudio multicéntrico en mujeres venezolanas / Contraceptive vaginal ring (MyRing®): multicenter study in Venezuelan women

Objetivo: Evaluar los factores asociados al uso del anillo vaginal en mujeres venezolanas en edad reproductiva, con deseo de anticoncepción y con vida sexual activa. Métodos: Estudio observacional - descriptivo, multicéntrico. La muestra fue de tipo no probabilística, deliberada y de voluntarias. Se les proporcionó el anillo vaginal por tres ciclos y las consultas de seguimiento se realizaron al final del primer y tercer ciclo menstrual. Se evaluó la aceptabilidad, tolerabilidad, cumplimiento, control de ciclo menstrual y la presencia de efectos adversos. Resultados: Se incluyeron 140 mujeres, con edad promedio de 31,01 años ± 8,14. Los motivos de selección del anillo vaginal fueron: evita embarazo de manera efectiva (69,29 %), fácil de usar (68,57 %), uso mensual (65,71 %). El patrón de sangrado fue reportado como regular en 95 % de las mujeres en la segunda consulta y en 92,8 % en la tercera; 88,57 % reportó ausencia de sangrado intermenstrual. Hubo cumplimiento adecuado en 97,86 %; 96,43 % expresó que era fácil de usarlo y 92,86 % comodidad a nivel sexual. No hubo diferencias estadísticas significativas en el peso promedio en la segunda y tercera consulta (p > 0,05), ni en la tensión arterial sistólica y diastólica (p > 0,05). No hubo eventos adversos en 77 %, cuando los hubo, los más frecuentes fueron cefalea, náuseas y mastodinia; no hubo eventos adversos serios, ni embarazo. Conclusión: El anillo vaginal anticonceptivo es una opción bien tolerada con excelente aceptación, satisfacción sexual y general, segura, con escasos eventos adversos(AU)

Objective: To evaluate the factors associated with the use of the vaginal ring in Venezuelan women of reproductive age, with a desire for contraception and with an active sexual life. Methods: Observational - descriptive, multicenter study. The sample was non-probabilistic, deliberate and voluntary. The vaginal ring was provided for three cycles and follow-up visits were made at the end of the first and third menstrual cycles. Acceptability, tolerability, compliance, menstrual cycle control, and the presence of adverse effects were evaluated. Results: A total of 140 women were included, whose mean age was 31.01 ± 8.14 years. The reasons for selecting the vaginal ring were: effectively prevents pregnancy (69.29 %), easy to use (68.57 %), method of monthly use (65.71 %). The bleeding pattern was reported as regular in 95% of the women in the second consultation and in 92.8% in the third; 88.57% reported absence of intermenstrual bleeding. There was adequate compliance in 97.86%; 96.43% expressed that it was easy to use and 92.86% comfortable at a sexual level. There were no statistically significant differences in the average weight at the second and third consultation (p > 0.05), nor in systolic and diastolic blood pressure (p > 0.05). There were no adverse events in 77%, when there were, the most frequent were headache, nausea and mastodynia; there were no serious adverse events or pregnancy. Conclusion: The contraceptive vaginal ring is a well-tolerated option with excellent acceptance, sexual and general satisfaction, safe, with few adverse events(AU)

Eritema nodoso asociado al uso de anillo vaginal anticonceptivo / Erythema nodosum associated with the use of contraceptive vaginal ring

El eritema nodoso (EN) es la forma de paniculitis más común. Este trastorno representa una reacción de hipersensibilidad frente a diferentes antígenos, así como múltiples enfermedades sistémicas y fármacos, aunque en la mayoría de casos se desconoce la causa. Nuevos fármacos se añaden a la lista de involucrados en la etiopatogenia del eritema nodoso conforme van pasando los años, siendo uno de ellos los anticonceptivos hormonales orales combinados. El objetivo de este trabajo es proponer una relación entre los estrógenos de cualquier método anticonceptivo como puede ser el anillo vaginal combinado y la aparición del eritema nodoso.

Erythema nodosum (EN) is the most common form of panniculitis. This disorder represents a hypersensitivity reaction in front of different antigens, as well as multiple systemic diseases and drugs, although in most cases the cause is unknown. New drugs are added to the list of those involved in the etiopathogenesis of erythema nodosum as the years go by, one of them being combined oral hormonal contraceptives. The objective of this study is to propose a relationship between estrogens from any contraceptive method such as the combined vaginal ring and the appearance of erythema nodosum.

Advances in contraceptive vaginal rings: what does the future hold?

INTRODUCTION: Contraceptive vaginal rings (CVRs) are good contraceptive options because they do not require skilled providers, are self-administered, and show a higher stability of drug diffusion. AREAS COVERED: This article provides a review of the developments made with CVRs over the past number of years, while giving focus to the latest CVRs that have gone through clinical development. The author of the article also provides an expert perspective on the future of these useful therapeutic options. EXPERT OPINION: Pharmacokinetic studies have shown that segesterone, an absorbable progestin that is used alone or in combination with ethinyl estradiol (EE) or E2, is the CVR of choice at this present time. Indeed, segesterone has demonstrated safety and efficacy as a CVR and is also an appropriate option for lactating women, as they are not absorbed orally. However, good cycle control is important for improved CVR adherence. CVRs that allow the combination of more than one drug may unravel another multi-purpose use when combined with microbicides and could provide combined protection to women who wish to protect themselves from pregnancy and sexually transmitted infection.